News | Computed Tomography (CT) | May 20, 2026

CT scanner installation at Italian research center will support the development of next-generation contrast agents and AI-enabled imaging.

Bracco to Install Photon-Counting CT Scanner at Research Center

MARS Bioimaging Scanner System
Photo: MARS Bioimaging


May 12, 2026 – Bracco Imaging S.p.A. has purchased a mobile photon-counting CT scanner from MARS Bioimaging to support its contrast agent and artificial intelligence research.

The MARS Bioimaging Scanner System will be installed at Bracco’s Research Center (CRB) in Colleretto Giacosa, Italy, a facility focused on the development and innovation of contrast agents for X-ray/CT and MR imaging.

Bracco Imaging lead investigator, Alberto Fringuello Mingo, said, “The acquisition of the MARS photon-counting CT scanner is supported by ‘Fondo Italiano per le Scienze Applicate’ funded research project (grant: FISA-2023-00298), led by Principal Investigator Prof. Angelo Bifone of the University of Turin. This project will investigate how AI and advanced imaging can be combined to enhance diagnostic outcomes, also leveraging the unique capabilities of photon-counting CT — such as spectral imaging and material decomposition — to achieve improved characterization of contrast.”

The MARS Bioimaging Extremity Scanner System received U.S. Food and Drug Administration (FDA) 510(k)  clearance in March 2026, providing  important validation to support regulatory pathways and market adoption globally.

Mark Figgitt, Group COO, MARS Bioimaging, added, “MARS scanners deliver high-resolution 3D X-ray imaging that visualizes soft tissue, bone, blood vessels and metallic implants with clear material differentiation, enabling new insights into how contrast agents can enhance diagnostic performance. Importantly, researchers can also readily access underlying data in an efficient workflow designed to add value to clinical research projects.”

The MARS scanner leverages advanced photon-counting detector technology developed originally through particle physics research at the European Laboratory for Particle Physics (CERN), home of the Higgs boson discovery. MARS Bioimaging holds the exclusive license from CERN to commercialize this Medipix3 technology for medical imaging of extremities at the point-of-care and for mobile scanners for clinical research.

 

MARS Bioimaging Bracco CT scanner

 


Related Content

News | Ultrasound Imaging

July 7, 2026 — Longeviti Neuro Solutions has launched a new strategic initiative, ClearFit AI, a Brain Ultrasound ...

Time July 09, 2026
arrow
News | Prostate Cancer

July 8,2026 — CorePlus, Puerto Rico’s fully digital precision pathology and clinical laboratory, has announced the ...

Time July 08, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

July 7, 2026 — Imagion Biosystems, Ltd. recently announced it has renewed and extended its collaboration agreement with ...

Time July 07, 2026
arrow
News | Women's Health

July 1, 2026 — Despite declining birth rates worldwide, the complexity of pregnancy is increasing. Advanced maternal age ...

Time July 01, 2026
arrow
News | Information Technology

June 26, 2026 — Radin Health recently announced the successful deployment of its cloud-native platform at four ...

Time June 26, 2026
arrow
News | FDA

June 25, 2026 — Aidoc recently announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device ...

Time June 25, 2026
arrow
News | Mammography

June 23, 2026 — Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer ...

Time June 24, 2026
arrow
News | Pediatric Imaging

June 16, 2026 — Crescom has officially launched a global clinical Proof of Concept (PoC) of its pediatric ...

Time June 24, 2026
arrow
News | Information Technology

June 24, 2026 — HOPPR Presto Agent (Presto) is now commercially available from HOPPR. Presto iis a tool that ntegrates ...

Time June 24, 2026
arrow
News | Digital Pathology

June 17, 2026 — Proscia has introduced the Fifth Generation of its Concentriq1 platform, helping pathologists focus on ...

Time June 22, 2026
arrow
Subscribe Now